We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
1
American Psychiatric Association (APA).
Diagnostic and statistical manual of mental disorders, 4th edn, text edition. Washington: American Psychiatric Association, 2000.
Google ScholarPubMed
2
Mulrow, CD,
Williams, JW,
Trivedi, Met al. Treatment of depression: newer pharmacotherapies.
Evid Rep Technol Assess (Summ)1999;7:1–4.
Google Scholar
3
Asher, JA,
Cole, JO,
Colin, JNet al. Bupropion: a review of its mechanism of antidepressant activity.
J Clin Psychiatry1995;56:395–401.
Google Scholar
4
Papakostas, GI.
Dopaminergic-based pharmacotherapies for depression.
Eur Neuropsychopharmacol2006;16:391–402.
CrossRefGoogle Scholar
5
San, L,
Arranz, B.
Mirtazapine: only for depression?Acta Neuropsychiatr2006;18:130–143.
CrossRefGoogle Scholar
6
ÁLamo, C,
López-Muñoz, F,
Rubio, G,
García-García, P,
Pardo, A.
Combined treatment with reboxetine in depressed patients with no response to venlafaxine: a 6-week follow-up study.
Acta Neuropsychiatr2007;19:291–296.
CrossRefGoogle ScholarPubMed